Preservation of CCR7⁺ CD4⁺ T cells at day 30 is associated with improved survival after CBT. We examined actuarial survival in patients stratified by the median ratio of CCR7⁺ to CCR7⁻CD4⁺ T cells at post-CBT day 30. Patients above the median ratio had significantly improved survival after CBT (median survival 240 days vs 700 days, P = .013).